Study the Effect of Omeprazole on AB-106 Pharmacokinetics
Status:
Not yet recruiting
Trial end date:
2023-01-08
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, fixed sequence phase I clinical study. To evaluate the
effect of continuous administration of omeprazole magnesium enteric coated tablets on PK
after single dose AB-106 capsule administration in Chinese healthy male subjects. This study
includes a screening period (1-28 days before administration), treatment period (34 days),
and follow-up period ( after the last dose completed 7 ± 3 days). The treatment period of
this study was divided into two periods, and the subjects were divided into two groups, 12
subjects in the first group and 10 subjects in the second group. The treatment method and
research process of each group of subjects are the same. After the first group of subjects
completes the second cycle and is evaluated by the investigator and sponsor, the second group
of subjects can start administration. If there are no more than 4 subjects in the first group
who have vomiting gastrointestinal reaction (vomiting occurs within 8 hours after each cycle
of administration) after completing the two cycles of administration of AB-106 400 mg, they
can be added to the second group of subjects, and the number of added subjects shall not
exceed the number of subjects who have vomiting gastrointestinal reaction. If more than 4
subjects have gastrointestinal reaction of vomiting, the investigator and sponsor will make a
comprehensive evaluation, and can reduce the dosage of AB-106 to 200 mg, and 22 subjects will
be included in the trial at one time or supplemented in the second group to complete the 400
mg dose group